Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ

TXNIP overexpression suppresses proliferation and induces apoptosis in SMMC7221 cells through ROS generation and MAPK pathway activation

(2017) Jian Li et al.   ONCOLOGY REPORTS

Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study

(2016) Shusma C. Doebar et al.   BREAST CANCER RESEARCH AND TREATMENT

Predictors of Recurrent Ductal CarcinomaIn Situafter Breast-Conserving Surgery

(2016) Jung Yeon Kim et al.   Journal of Breast Cancer

Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ

(2016) Ann C. Raldow et al.   JOURNAL OF CLINICAL ONCOLOGY

Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast

(2015) Amanda Arantes Perez et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Copy number analysis of ductal carcinoma in situ with and without recurrence

(2015) Kylie L Gorringe et al.   MODERN PATHOLOGY

Updated UK Recommendations for HER2 assessment in breast cancer

(2014) Emad A Rakha et al.   JOURNAL OF CLINICAL PATHOLOGY

Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer

(2014) Jennifer A Morrison et al.   Molecular Cancer

Radiotherapy in DCIS, an underestimated benefit?

(2014) Bruno Cutuli et al.   RADIOTHERAPY AND ONCOLOGY

Thioredoxin/Txnip: Redoxisome, as a Redox Switch for the Pathogenesis of Diseases

(2014) Eiji Yoshihara et al.   Frontiers in Immunology

Ductal carcinomain situof the breast: morphological and molecular features implicated in progression

(2013) Dirce M. Carraro et al.   BIOSCIENCE REPORTS

A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast

(2013) L. J. Solin et al.   JNCI-Journal of the National Cancer Institute

Thioredoxin System in Cell Death Progression

(2012) Jun Lu et al.   ANTIOXIDANTS & REDOX SIGNALING

Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer

(2012) Jianbiao Zhou et al.   MITOCHONDRION

The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer

(2012) Caroline M Woolston et al.   MODERN PATHOLOGY

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

Thioredoxin-interacting protein suppresses bladder carcinogenesis

(2011) Koji Nishizawa et al.   CARCINOGENESIS

TXNIP (VDUP-1, TBP-2): A major redox regulator commonly suppressed in cancer by epigenetic mechanisms

(2011) Jianbiao Zhou et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1

(2011) H-O Jin et al.   ONCOGENE

The Emerging Role of the Thioredoxin System in Angiogenesis

(2010) Louise L. Dunn et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009

(2010) C. J. Allegra et al.   JNCI-Journal of the National Cancer Institute

The NLRP3 Inflammasome: A Sensor for Metabolic Danger?

(2010) K. Schroder et al.   SCIENCE

Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results

(2009) Yun Gong et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast

(2008) A. Vincent-Salomon et al.   CLINICAL CANCER RESEARCH